Jade Biosciences, Inc. (JBIO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company developing biologic therapies for autoimmune diseases. The reporting period covers the three and nine months ended September 30, 2025. The company operates as a single segment focused on the development of its lead product candidate, JADE101 (targeting APRIL for IgA nephropathy), JADE201 (targeting BAFF-R), and JADE-003. On April 28, 2025, the company consummated a reverse recapitalization with Aerovate Therapeutics, Inc., becoming a public company listed on the Nasdaq Capital Market under the symbol "JBIO."
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(25.2) million | $(95.5) million | N/A |
| Operating Expenses | $(27.4) million | $(78.6) million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $50.1 million |
| Investments | N/A | N/A | $148.8 million |
| Total Liquidity | N/A | N/A | $198.9 million |
| Debt | $0 | $0 | $0 |
Note: All figures in millions unless otherwise noted. The company has no revenue and no outstanding debt as of September 30, 2025, following the conversion of convertible notes into equity.
Material Changes vs. Prior Period
- Reverse Recapitalization: The most significant change was the April 2025 merger with Aerovate Therapeutics, Inc., which converted all outstanding Series Seed Preferred Stock and Convertible Notes into common stock and Series A Preferred Stock. Consequently, long-term debt of $107.6 million recorded at December 31, 2024, was eliminated.
- Operating Expenses: Total operating expenses increased to $27.4 million for Q3 2025 from $15.0 million in Q3 2024. This increase was driven by higher R&D spend ($22.0M vs $13.6M) due to clinical trial initiation for JADE101 and JADE201, and increased G&A ($5.4M vs $1.4M) associated with public company operations.
- Net Loss: Net loss for the nine months ended September 30, 2025, was $95.5 million, compared to $16.9 million for the period from inception (June 18, 2024) through September 30, 2024. The increase includes a $21.6 million non-cash charge related to the change in fair value of convertible notes prior to their conversion.
- Liquidity Position: Cash and investments increased significantly from $69.4 million at year-end 2024 to $198.9 million at September 30, 2025, primarily due to the Pre-Closing Financing and the merger.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur significant losses for the foreseeable future. The company anticipates that its existing liquidity of approximately $198.9 million, combined with $135 million in gross proceeds from a private placement closed in October 2025, will fund operations for at least 12 months.
- Development Milestones: The company initiated a Phase 1 clinical trial for JADE101 in healthy volunteers in New Zealand in August 2025. JADE201 is in pre-clinical development.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, reliance on third-party manufacturers (including WuXi Biologics), and potential regulatory changes (e.g., the BIOSECURE Act). The company has no products approved for sale and no revenue.
- Unusual Items: The nine-month net loss included a $21.6 million non-cash expense for the change in fair value of convertible notes payable, which was recorded prior to their conversion into equity in April 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $198.9 million liquidity position against the projected burn rate, considering the recent $135 million private placement.
- Related Party Transactions: Review the terms of the Paragon Option Agreement and License Agreements, noting that Paragon (affiliated with Fairmount, a significant shareholder) performs a substantial portion of R&D and receives milestone payments.
- Convertible Note Conversion: Confirm the details of the April 2025 conversion of $95 million in convertible notes into common stock and pre-funded warrants, ensuring no remaining debt obligations exist.
- Stock-Based Compensation: Assess the impact of the $10.6 million stock-based compensation expense for the nine months ended September 30, 2025, on future dilution.
- Manufacturing Dependencies: Evaluate the risks associated with reliance on third-party contract manufacturing organizations (CMOs), particularly regarding geopolitical risks and the BIOSECURE Act.